Search

Your search keyword '"Nowakowski G"' showing total 21 results
Start Over Author "Nowakowski G" Publisher wiley
21 results on '"Nowakowski G"'

1. Overall survival in classic Hodgkin lymphoma pts who progress after autologous stem cell transplant in the era of novel agents

Author

Desai, S. H., primary, Spinner, M., additional, Evens, A. M., additional, Bachanova, V., additional, Goyal, G., additional, Kahl, B., additional, Dorritie, K., additional, Azzi, J., additional, Kenkre, V. P., additional, Arai, S., additional, Chang, C., additional, Fusco, B., additional, Sumransub, N., additional, Hatic, H., additional, Saba, R., additional, Ibrahim, U., additional, Harris, E. I., additional, Ansell, S. M., additional, Shah, H., additional, Wagner‐Johnston, N., additional, Jagadeesh, D., additional, Blum, K. A., additional, Diefenbach, C., additional, Iyenger, S., additional, Rapazzo, K. C., additional, Baidoun, F., additional, Choi, Y., additional, Nowakowski, G. S., additional, Advani, R. H., additional, and Micallef, I. N., additional

Published
2023
Full Text
View/download PDF

3. THREE PHASE 1/2, OPEN‐LABEL STUDIES OF CEREBLON E3 LIGASE MODULATOR (CELMOD)‐BASED REGIMENS IN NEWLY DIAGNOSED (ND) OR RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL)

Author

Morschhauser, F., primary, Nowakowski, G. S., additional, Cartron, G., additional, Kesanakurthy, V., additional, Gkasiamis, A., additional, Patah, P., additional, Delarue, R., additional, Wang, T., additional, Li, J., additional, Xian, D., additional, Fox, C. P., additional, and Martin, P., additional

Published
2021
Full Text
View/download PDF

5. INTERIM PET/CT PREDICTS OUTCOMES OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH FRONTLINE LENALIDOMIDE/RCHOP (R2CHOP): LONG‐TERM ANALYSIS OF MC078E

Author

Desai, S., primary, Laplant, B., additional, Macon, W., additional, Young, J., additional, King, R., additional, Wang, Y., additional, Inwards, D., additional, Micallef, I., additional, Johnston, P. B., additional, Porrata, L. F., additional, Ansell, S. M., additional, Habermann, T. M., additional, Witzig, T. E., additional, and Nowakowski, G. S., additional

Published
2021
Full Text
View/download PDF

6. INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: INTERIM ANALYSIS FROM THE PHASE 3B MAGNIFY STUDY

Author

Sharman, J. P., primary, Melear, J. M., additional, Yacoub, A., additional, Fanning, S. R., additional, Andorsky, D. J., additional, Nowakowski, G. S., additional, Rummel, M. J., additional, Lansigan, F., additional, Li, J., additional, Ahn, J. R., additional, Gharibo, M., additional, and Coleman, M., additional

Published
2021
Full Text
View/download PDF

7. PRIMARY EXTRANODAL FOLLICULAR LYMPHOMA IN A LARGE RETROSPECTIVE SURVEY OF THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG31)

Author

Conconi, A., primary, Vannata, B., additional, Janikova, A., additional, Ramirez, A., additional, Bodoni, C. Lobetti, additional, Nowakowski, G., additional, Mian, M., additional, Ferreri, Andrés J.M., additional, Ryan, G., additional, Pangalis, G. A., additional, Cabrera, M. E., additional, Luminari, S., additional, Montoto, S., additional, Tsang, R., additional, Aurer, I., additional, Visco, C., additional, Mazzucchelli, L., additional, Trneny, M., additional, Gaidano, G., additional, Federico, M., additional, Lopez‐Guillermo, A., additional, Pro, B., additional, and Zucca, E., additional

Published
2021
Full Text
View/download PDF

8. INDUCTION R 2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY TRANSFORMED FOLLICULAR LYMPHOMA: INTERIM ANALYSIS FROM THE PHASE 3B MAGNIFY STUDY

Author

. Lansigan, F, primary, . Parameswaran, V, additional, . Yacoub, A, additional, . Reynolds, C. M, additional, . Shao, S. H, additional, . Moore, S. G, additional, . Coleman, M, additional, . Andorsky, D. J, additional, . Nowakowski, G. S, additional, . Rummel, M. J, additional, . Li, J, additional, . Ahn, J. R, additional, . Gharibo, M, additional, and . Sharman, J. P, additional

Published
2021
Full Text
View/download PDF

9. FIRST‐MIND: A PHASE IB, OPEN‐LABEL, RANDOMIZED STUDY TO ASSESS SAFETY OF TAFASITAMAB OR TAFASITAMAB + LENALIDOMIDE IN ADDITION TO R‐CHOP IN PATIENTS WITH NEWLY DIAGNOSED DLBCL

Author

Belada, D, primary, Kopeckova, K, additional, Bergua Burgues, J. M, additional, André, M, additional, Pérez Persona, E, additional, Pichler, P, additional, Klöpfer, P, additional, Brackertz, B, additional, Lohrmann, E, additional, Lahiry, A, additional, Shah, N, additional, Brugger, W, additional, Burke, J. M, additional, and Nowakowski, G. S, additional

Published
2021
Full Text
View/download PDF

10. IMPACT OF TIME TO RELAPSE AND RESPONSE TO SALVAGE THERAPY ON POST AUTOLOGOUS STEM CELL TRANSPLANT OUTCOMES IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Author

Tun, A. M, primary, Wang, Y, additional, Maliske, S, additional, Farooq, U, additional, Micallef, I. N, additional, Inwards, D. J, additional, Porrata, L. F, additional, Ansell, S. M, additional, Rosenthal, A. C, additional, Kharfan‐Dabaja, M, additional, Link, B. K, additional, Villasboas, J. C, additional, Paludo, J, additional, Cerhan, J. R, additional, Habermann, T. M, additional, Witzig, T. E, additional, Nowakowski, G. S, additional, and Johnston, P. B, additional

Published
2021
Full Text
View/download PDF

12. DO CELL‐OF‐ORIGIN, DOUBLE EXPRESSER, AND DOUBLE HIT STATUS AFFECT OUTCOMES IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (R/R DLBCL)? A PROSPECTIVE OBSERVATIONAL STUDY

Author

Desai, S. H., primary, Mwangi, R., additional, Maurer, M., additional, King, R., additional, Cerhan, J., additional, Feldman, A., additional, Habermann, T., additional, Farooq, U., additional, Thompson, C., additional, Wang, Y., additional, Ansell, S. M., additional, Witzig, T. E., additional, and Nowakowski, G. N., additional

Published
2021
Full Text
View/download PDF

13. PROGRESSION‐FREE SURVIVAL AT 24 MONTHS AS A LANDMARK AFTER AUTOLOGOUS STEM CELL TRANSPLANT IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Author

Tun, A. M, primary, Maliske, S, additional, Wang, Y, additional, Maurer, M. J, additional, Micallef, I. N, additional, Inwards, D. J, additional, Porrata, L. F, additional, Rosenthal, A. C, additional, Kharfan‐Dabaja, M, additional, Orme, J, additional, Link, B. K, additional, Cerhan, J. R, additional, Thompson, C. A, additional, Habermann, T. M, additional, Witzig, T. E, additional, Ansell, S. M, additional, Nowakowski, G. S, additional, Farooq, U, additional, and Johnston, P. B, additional

Published
2021
Full Text
View/download PDF

14. Relapsed / Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma

Author

Maurer, MJ, Jakobsen, LH, Mwangi, R, Schmitz, N, Farooq, U, Flowers, CR, de Nully Brown, P, Thompson, CA, Frederiksen, H, Cunningham, D, Jorgensen, J, Poeschel, V, Nowakowski, G, Seymour, JF, Merli, F, Haioun, C, Ghesquieres, H, Ziepert, M, Tilly, H, Salles, G, Shi, Q, El-Galaly, TC, Habermann, TM, Maurer, MJ, Jakobsen, LH, Mwangi, R, Schmitz, N, Farooq, U, Flowers, CR, de Nully Brown, P, Thompson, CA, Frederiksen, H, Cunningham, D, Jorgensen, J, Poeschel, V, Nowakowski, G, Seymour, JF, Merli, F, Haioun, C, Ghesquieres, H, Ziepert, M, Tilly, H, Salles, G, Shi, Q, El-Galaly, TC, and Habermann, TM

Abstract

Disease progression after frontline therapy for Diffuse large B-cell lymphoma (DLBCL) is a clinically significant event. Patients who experience early progression or have refractory disease have especially poor outcomes. Simple, clinically applicable prognostic tools are needed for selecting patients for consideration for novel therapies and prognostication in the relapsed/refractory (R/R) setting. Model building was performed in patients from the Surrogate endpoints in aggressive lymphoma (SEAL) consortium with disease progression after frontline immunochemotherapy. The primary endpoint was overall survival (OS) measured from date of progression. Validation was performed in the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource (MER) and Danish National Lymphoma Register (LYFO) cohorts. Model performance was assessed using time-dependent concordance indices (c-statistic) and calibration with metrics evaluated at 2 years from progression. Note, 1234 of 5112 patients treated with frontline immunochemotherapy in the SEAL consortium developed progressive disease. Time to progression on immunochemotherapy and age at progression were strongly associated with post-progression OS (both p < 0.001). A prognostic model was developed incorporating spline fit for both variables. The model had good concordance in the discovery (0.67) and validation sets (LYFO c = 0.64, MER c = 0.68) with generally good calibration. Time to progression on frontline therapy is strongly associated with post-progression OS in DLBCL. We developed and validated a simple to apply clinical prognostic tool in the R/R setting. The useful prediction of expected outcomes in R/R DLBCL and can inform treatment decisions such as considerations for CAR-T therapy as well as trial designs. The model is available in smartphone-based point of care applications.

Published
2021

15. SAFETY AND EFFICACY OF THE PD-L1 INHIBITOR DURVALUMAB WITH R-CHOP OR R2 -CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH-RISK DLBCL

Author

Nowakowski, G., primary, Willenbacher, W., additional, Greil, R., additional, Larsen, T.S., additional, Patel, K., additional, Jäger, U., additional, Manges, R.F., additional, Trümper, L., additional, Haioun, C., additional, Everaus, H., additional, Kalakonda, N., additional, Knoble, J., additional, de Nully Brown, P., additional, Jørgensen, J.M., additional, Cunningham, D., additional, Domper Rubio, N., additional, Casadebaig, M., additional, Manzke, O., additional, and Munoz, J., additional

Published
2019
Full Text
View/download PDF

16. AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2 ) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS

Author

Leonard, J., primary, Trneny, M., additional, Izutsu, K., additional, Fowler, N., additional, Hong, X., additional, Zhang, H., additional, Offner, F., additional, Scheliga, A., additional, Nowakowski, G., additional, Pinto, A., additional, Re, F., additional, Fogliatto, L., additional, Scheinberg, P., additional, Flinn, I., additional, Moreira, C., additional, Czuczman, M., additional, Kalambakas, S., additional, Fustier, P., additional, Wu, C., additional, and Gribben, J., additional

Published
2019
Full Text
View/download PDF

17. PRE-TREATMENT HEMOGLOBIN AND OUTCOME IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ANTHRACYCLINE CONTAINING CHEMOTHERAPY

Author

Clausen, M.R., primary, Maurer, M., additional, Ulrichsen, S.P., additional, Larsen, T.S., additional, Himmelstrup, B., additional, Ronnov-Jessen, D., additional, Link, B., additional, Feldman, A., additional, Slager, S., additional, Nowakowski, G., additional, Thompson, C., additional, Pedersen, P.T., additional, Madsen, J., additional, Pedersen, R.S., additional, Gørløv, J.S., additional, Cerhan, J.R., additional, and d'Amore, F., additional

Published
2019
Full Text
View/download PDF

18. POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2 ) VS RITUXIMAB/PLACEBO (AUGMENT)

Author

Thieblemont, C., primary, Leonard, J., additional, Trneny, M., additional, Izutsu, K., additional, Fowler, N., additional, Hong, X., additional, Zhang, H., additional, Offner, F., additional, Scheliga, A., additional, Nowakowski, G., additional, Pinto, A., additional, Re, F., additional, Fogliatto, L., additional, Scheinberg, P., additional, Flinn, I., additional, Moreira, C., additional, Czuczman, M., additional, Kalambakas, S., additional, Fustier, P., additional, Wu, C., additional, and Gribben, J., additional

Published
2019
Full Text
View/download PDF

19. AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2 ) THAN RITUXIMAB/PLACEBO

Author

Gribben, J., primary, Trneny, M., additional, Izutsu, K., additional, Fowler, N.H., additional, Hong, X., additional, Zhang, H., additional, Offner, F., additional, Scheliga, A., additional, Nowakowski, G., additional, Pinto, A., additional, Re, F., additional, Fogliatto, L., additional, Scheinberg, P., additional, Flinn, I., additional, Moreira, C., additional, Czuczman, M., additional, Kalambakas, S., additional, Fustier, P., additional, Wu, C., additional, and Leonard, J., additional

Published
2019
Full Text
View/download PDF

20. HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2 ) VERSUS R PLUS PLACEBO

Author

Leonard, J.P., primary, Trněny, M., additional, Izutsu, K., additional, Fowler, N.H., additional, Hong, X., additional, Zhang, H., additional, Offner, F., additional, Scheliga, A., additional, Nowakowski, G., additional, Pinto, A., additional, Re, F., additional, Fogliatto, L.M., additional, Scheinberg, P., additional, Flinn, I.W., additional, Moreira, C., additional, Tabah, A., additional, Abouzaid, S., additional, Kalambakas, S., additional, Fustier, P., additional, Wu, C., additional, and Gribben, J.G., additional

Published
2019
Full Text
View/download PDF

21. Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia

Author

Nowakowski, G. S., primary, Dewald, G. W., additional, Hoyer, J. D., additional, Paternoster, S. F., additional, Stockero, K. J., additional, Fink, S. R., additional, Smoley, S. A., additional, Remstein, E. D., additional, Phyliky, R. L., additional, Call, T. G., additional, Shanafelt, T. D., additional, Kay, N. E., additional, and Zent, C. S., additional

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results